Patents Assigned to The United States of America,as represented by the Secretary, Department of Health and Human Servic
  • Publication number: 20210154288
    Abstract: Immunogenic compositions that include a bacterial capsular polysaccharide conjugated to a carrier protein are described. In some embodiments, the bacterial capsular polysaccharide is a Neisseria meningitidis capsular polysaccharide. The carrier protein includes an N. meningitidis factor H binding protein (fHbp) linked to cholera toxin subunit B (CTB). Administration of the immunogenic compositions elicits an immune response that includes production of meningococcal polysaccharide-specific and fHbp-specific antibodies. Use of the immunogenic compositions as meningococcal vaccines is also described.
    Type: Application
    Filed: December 18, 2018
    Publication date: May 27, 2021
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Gregory A. Price, Che-Hung Robert Lee, Margaret Bash
  • Publication number: 20210138028
    Abstract: In embodiments, the invention provides a method of treating or preventing an adverse condition of the liver of a mammal, the method comprising administering to the mammal an effective amount of vancomycin and a checkpoint inhibitor. In embodiments, the invention provides a method of treating or preventing an adverse condition of the liver of a mammal, the method comprising administering to the mammal an effective amount of a primary bile acid.
    Type: Application
    Filed: October 29, 2018
    Publication date: May 13, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Tim F. Greten, Chi Ma
  • Publication number: 20210139440
    Abstract: This disclosure concerns fatty acid derivatives, pharmaceutical compositions comprising the fatty acid derivatives, and methods of using the fatty acid derivatives, for example, to treat inflammation, chronic itch, chronic pain, an autoimmune disorder, atherosclerosis, a skin disorder, arthritis, a neurodegenerative disorder, or a psychiatric disorder in a subject. In some embodiments, the fatty acid derivative is a compound, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, having a structure according to: wherein X is from 1-16 carbons in length, Z is aliphatic from 1-16 carbons in length, or is not present, Y is selected from: R1, R2, and R3 are independently hydrogen or lower alkyl, R4 is lower alkyl, hydroxyl, carboxyl, or amine, R5 is hydrogen, lower alkyl, or halide, R6 is hydroxyl or substituted thiol, and each R7 is independently hydrogen or fluoride or is not present and the adjacent carbons form alkyne.
    Type: Application
    Filed: July 6, 2018
    Publication date: May 13, 2021
    Applicant: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human servic
    Inventors: Christopher Ramsden, Gregory Keyes
  • Publication number: 20210113705
    Abstract: A process for producing a peptide antigen conjugate suitable for administration to a mammal is disclosed. The peptide antigen conjugate comprises a peptide antigen linked to a hydrophobic block. The process comprises reacting a hydrophobic block fragment with a peptide antigen fragment comprising the peptide antigen in a pharmaceutically acceptable organic solvent in a hydrophobic block fragment to peptide antigen fragment molar ratio of 1:1 or greater under conditions to directly or indirectly link the peptide antigen to the hydrophobic block and obtaining a product solution comprising the peptide antigen conjugate, unreacted hydrophobic block fragment and pharmaceutically acceptable organic solvent.
    Type: Application
    Filed: May 22, 2019
    Publication date: April 22, 2021
    Applicants: Avidea Technologies, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Geoffrey Martin Lynn, Andrew Scott Ishizuka, Vincent Coble, Yaling Zhu
  • Publication number: 20210100919
    Abstract: Heptamethine cyanines for use as fluorescent markers of the biliary and renal systems are disclosed. Certain heptamethine cyanines exhibit renal system specificity, while others exhibit biliary system specificity. The compounds may be used for diagnostic purposes and/or for visualization of renal or biliary systems during surgery.
    Type: Application
    Filed: February 14, 2019
    Publication date: April 8, 2021
    Applicants: CHILDREN'S NATIONAL MEDICAL CENTER, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Martin John SCHNERMANN, Peter C.W. KIM, Jaepyeong CHA, Roger Rauhauser NANI
  • Publication number: 20210079070
    Abstract: Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
    Type: Application
    Filed: February 21, 2019
    Publication date: March 18, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Paolo Lusso, Qingbo Liu, Peter Kwong, John Mascola, Young Do Kwon
  • Publication number: 20210023208
    Abstract: Embodiments of a novel system for delivering an expression vector encoding an antigen to a subject that allows for spatiotemporal control over stimulation of the subject's immune response to the antigen are provided. In some embodiments, the expression vector delivery system includes a polymer linked to an adjuvant in prodrug form that can form polymer nanoparticles and enter a cell (such as an immune cell) under physiological conditions. In some embodiments, the adjuvant is linked to the polymer by an enzyme degradable labile bond, the cleavage of which activates the adjuvant to stimulate an immune response.
    Type: Application
    Filed: October 6, 2020
    Publication date: January 28, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Robert Seder, Geoffrey Lynn, Leonard Seymour
  • Publication number: 20210010914
    Abstract: This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 14, 2021
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Hisataka Kobayashi, Peter Choyke, Martin John Schnermann
  • Publication number: 20210000926
    Abstract: Provided are compositions and methods for treating a subject having a primary immune deficiency (PID), for example who is suffering from a chronic viral, bacterial, or fungal infection, using autologous granulocytes, autologous lymphocytes, and/or NK cells containing exogenous mRNA encoding the missing or defective protein.
    Type: Application
    Filed: February 19, 2019
    Publication date: January 7, 2021
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, CELLSCRIPT, LLC
    Inventors: Suk See De Ravin, Harry L. Malech, Ron Meis, Gary A. Dahl
  • Publication number: 20200383717
    Abstract: Disclosed monopolar and bipolar tissue lacerators can comprise a wire partially covered by electrical insulation, wherein the wire has a kink defining an inner curvature, wherein the wire is exposed through the insulation at one or two exposed regions along or near the inner curvature of the kink, wherein the wire is configured to conduct electrical energy through the one or two exposed regions and through a tissue target positioned adjacent the inner curvature to lacerate the tissue target via the electrical energy. The tissue target can be a native or prosthetic heart valve leaflet in a patient's heart.
    Type: Application
    Filed: February 19, 2019
    Publication date: December 10, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Robert J. Lederman, Jaffar M. Khan, Toby Rogers
  • Publication number: 20200360296
    Abstract: This disclosure provides novel peptide hydrogels containing encapsulated nanoparticles comprising nucleic acid molecules (such as miRNA) that can undergo multiple gel-to-solution (gel-sol) and solution-to-gel (sol-gel) phase transitions, and their use, such as for controlled delivery of nucleic acid molecules to a subject.
    Type: Application
    Filed: February 8, 2019
    Publication date: November 19, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Joel Schneider, Poulami Majumder, Chuong Hoang, Anand Singh
  • Publication number: 20200354468
    Abstract: Anti-CD133 monoclonal antibodies having advantageous properties, products, compositions and kits comprising the monoclonal antibodies, methods (processes) of making the monoclonal antibodies and related compositions, as well as methods of using the monoclonal antibodies in analytical, diagnostic and therapeutic applications.
    Type: Application
    Filed: June 12, 2020
    Publication date: November 12, 2020
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Thomas D. Pfister, Robert J. Kinders, Tony Navas
  • Publication number: 20200349700
    Abstract: A method for determining a quantity of interest related to the density of organic tissue starts with a digital representation of a histological image of the tissue. The digital representation is converted to a binary image, to discriminate pixels that represent tissue of interest in the image. A box filter is applied to values of the pixels of interest to obtain a tissue density value for each pixel of interest. A quantity of interest is computed, based upon the tissue density values for the pixels of interest. A tangible representation of the computed quantity of interest, such as a numerical value, a graph, or a color representation, is displayed or otherwise presented via an interface. Prior to forming the digital representation, the tissue can be stained to distinguish particular types of tissue for removal or enhancement in the determination of the quantity of interest.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 5, 2020
    Applicants: BIOCELLVIA, The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Jean-Claude Gilhodes, Yvon Julé, Tomi Florent, Bernadette R. Gochuico, M.D., Damien Barbes, Karine Bertotti
  • Publication number: 20200345829
    Abstract: This invention provides immunogenic compositions comprising an immune stimulant and an respiratory syncytial virus (RSV) oligopeptide or an unglycosylated RSV polypeptide. The RSV oligopeptides are shown in SEQ ID NO: 3-33. The unglycosylated RSV polypeptide may consist essentially of the ectodomain of an RSV G protein, such as that shown in SEQ ID NO: 2 or the ectodomain of an RSV F protein such as the ectodomain of the F protein shown in SEQ ID NO: 39.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 5, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Surender Khurana, Hana Golding
  • Publication number: 20200308128
    Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.
    Type: Application
    Filed: March 30, 2020
    Publication date: October 1, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
  • Publication number: 20200311384
    Abstract: Methods are disclosed for clustering biological samples and other objects using a grand canonical ensemble. A biological sample is characterized by data attributes from varying sources (e.g. NGS, other types of high-dimensional cytometric data, observed disease state) and of varying data types (e.g. Boolean, continuous, or coded sets) organized as vectors (as many as 109) having as many as 106, 109, or more components. The biological samples or observational data are modeled as particles of a grand canonical ensemble which can be variably distributed among partitions. A pseudo-energy is defined as a measure of inverse similarity between the particles. Minimization of grand canonical ensemble pseudo-energy corresponds to clustering maximally similar particles in each partition, thereby determining clusters of the biological samples. The sample clusters can be used for feature discovery, gene and pathway identification, and development of cell based therapeutics, or for other purposes.
    Type: Application
    Filed: November 15, 2018
    Publication date: October 1, 2020
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Elaine Ellen Thompson, Vahan Simonyan, Malcolm Moos, JR.
  • Publication number: 20200283507
    Abstract: Isolated VHH monoclonal antibodies are disclosed that specifically bind to a Norovirus polypeptide. In some embodiments, the Norovirus is a Genogroup I Norovirus or a Genogroup II Norovirus. In other embodiments, the Norovirus is Norwalk or MD2004 virus. In some embodiments, the monoclonal antibodies specifically bind VP1. Also disclosed are compositions including the disclosed antibodies, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of a Norovirus in a biological sample, or detecting a Norovirus infection. Also disclosed are methods of treating and/or preventing a NoV infection.
    Type: Application
    Filed: April 21, 2020
    Publication date: September 10, 2020
    Applicants: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Servic, INSTITUTO NACIONAL DE TECNOLOGIA AGROPECUARIA
    Inventors: Karin Bok, Lorena Laura Garaicoechea, Viviana Parreno, Andrea Pamela Aguilar, Marina Bok, Lisbeth Kim Green, Stanislav Vladimirovich Sosnovtsev
  • Publication number: 20200282020
    Abstract: Methods and compositions are disclosed for treating a subject with a cancer. The compositions can include a chimeric molecule comprising an agent that specifically binds the interleukin 4 receptor (IL-4R) and a toxic moiety, an interferon alpha (IFN?), and an interferon gamma (IFN?). In some non-liming embodiments, the compositions can also include monocytes. The methods disclosed herein include administering a therapeutically effective amount of the compositions taught herein to a subject with cancer, thereby treating the cancer in the subject, wherein cells in the cancer express IL-4R. In some non-liming embodiments, the methods can also include administering monocytes.
    Type: Application
    Filed: September 7, 2018
    Publication date: September 10, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Raj K. Puri, Kathryn C. Zoon, Syed R. Husain, Daniel S. Green
  • Publication number: 20200277338
    Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
    Type: Application
    Filed: May 18, 2020
    Publication date: September 3, 2020
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Servic
    Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
  • Publication number: 20200230229
    Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
    Type: Application
    Filed: October 3, 2017
    Publication date: July 23, 2020
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    Inventors: Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Michael Gordon Joyce, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong, Yongping Yang